Chemistry:Ziritaxestat
From HandWiki
Ziritaxestat is a small-molecule, selective autotaxin inhibitor that was investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF).[1] Initially showing promise in early-phase studies, ziritaxestat underwent evaluation in two large-scale phase 3 clinical trials, ISABELA 1 and ISABELA 2.[1][2] These trials aimed to assess the efficacy and safety of ziritaxestat in patients with IPF, including those receiving standard of care treatment with pirfenidone or nintedanib.[1] However, both trials were prematurely terminated due to a lack of efficacy, as ziritaxestat failed to demonstrate significant improvement in lung function or other clinical outcomes compared to placebo.[1][2][3]
References
- ↑ 1.0 1.1 1.2 1.3 "Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials". JAMA 329 (18): 1567–1578. May 2023. doi:10.1001/jama.2023.5355. PMID 37159034.
- ↑ 2.0 2.1 "Ziritaxestat Fails to Demonstrate Efficacy for Treatment of IPF in 2 Trials". HCPLive. 16 May 2023. https://www.hcplive.com/view/ziritaxestat-fails-to-demonstrate-efficacy-for-treatment-of-ipf-in-2-trials.
- ↑ "The future of clinical trials in idiopathic pulmonary fibrosis". Current Opinion in Pulmonary Medicine 30 (5): 494–499. September 2024. doi:10.1097/MCP.0000000000001099. PMID 38963152.
 |  |
